International Journal of Hematology最新文献_第7页

Long-term safety and efficacy of fostamatinib in Japanese patients with primary immune thrombocytopenia. 福司他替尼在日本原发性免疫性血小板减少症患者中的长期安全性和有效性。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-01 Epub Date: 2025-01-28 DOI: 10.1007/s12185-025-03924-2

Masataka Kuwana, Yoshiaki Tomiyama

{"title":"Long-term safety and efficacy of fostamatinib in Japanese patients with primary immune thrombocytopenia.","authors":"Masataka Kuwana, Yoshiaki Tomiyama","doi":"10.1007/s12185-025-03924-2","DOIUrl":"10.1007/s12185-025-03924-2","url":null,"abstract":"Fostamatinib had superior efficacy to a placebo and acceptable safety profiles for at least 1 year in a phase 3 study of Japanese patients with primary immune thrombocytopenia. Here, we report the 3-year safety and efficacy of fostamatinib in that study. Data from 33 patients who received at least one dose of fostamatinib were analyzed. A platelet response > 50,000/µL (at two consecutive visits at least 28 days apart while receiving fostamatinib) was achieved in 16 patients (48%). The median total duration of a platelet response > 50,000/µL was 589 (range: 106-1003) days. Gastrointestinal disorders, such as diarrhea, hypertension, and hepatic enzyme elevation, were the most common fostamatinib-related adverse events. Most events occurred within 12 weeks of treatment. No thromboembolisms, treatment-related infections, or moderate or severe treatment-related bleeding events were observed. In summary, this extension study of a clinical trial found a sustained platelet response without new safety signals during 3-year treatment with fostamatinib.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"356-362"},"PeriodicalIF":1.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11861395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding the intrinsic biology of diffuse large B-cell lymphoma: recent advances and future prospects. 了解弥漫大 B 细胞淋巴瘤的内在生物学特性：最新进展与未来展望。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-01 Epub Date: 2024-05-10 DOI: 10.1007/s12185-024-03780-6

Yusuke Naoi, Daisuke Ennishi

引用次数: 0

Correction: Treatment trends and risks of corticosteroid use in adult primary immune thrombocytopenia: a claims database study in Japan. 更正：皮质类固醇用于成人原发性免疫性血小板减少症的治疗趋势和风险：日本的一项索赔数据库研究。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-01 DOI: 10.1007/s12185-025-03931-3

Hirokazu Kashiwagi, Isao Miura, Naohiko Terasawa, Ken-Ichi Iwayama, Yuka Furukawa, Makoto Kanenishi

引用次数: 0

A 25-year clonal resurrection in adult T-cell leukemia-lymphoma relapse. 成人t细胞白血病淋巴瘤复发的25年克隆复活。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-01 Epub Date: 2024-12-25 DOI: 10.1007/s12185-024-03901-1

Atae Utsunomiya, Jun-Ichirou Yasunaga, Tomohisa Tabuchi, Nobuaki Nakano, Jun Odawara, Ayumu Kubota, Masahito Tokunaga, Takayoshi Miyazono, Masao Matsuoka, Yoshikiyo Ito, Yukie Tashiro

{"title":"A 25-year clonal resurrection in adult T-cell leukemia-lymphoma relapse.","authors":"Atae Utsunomiya, Jun-Ichirou Yasunaga, Tomohisa Tabuchi, Nobuaki Nakano, Jun Odawara, Ayumu Kubota, Masahito Tokunaga, Takayoshi Miyazono, Masao Matsuoka, Yoshikiyo Ito, Yukie Tashiro","doi":"10.1007/s12185-024-03901-1","DOIUrl":"10.1007/s12185-024-03901-1","url":null,"abstract":"Here, we report a rare case of relapsed adult T-cell leukemia-lymphoma (ATL) with evidence of clonal relapse 26 years after initial diagnosis. The patient had been diagnosed with an aggressive form of lymphoma-type ATL 26 years prior and did not receive further ATL treatment for approximately 26 years after achieving complete remission. We used nested PCR to identify the amplification of ATL clone-specific accumulation sites in DNA from hematoxylin and eosin-stained specimens from the patient. Furthermore, the sequence of amplicons obtained from peripheral blood mononuclear cells and lymphoma cells from the previously diagnosed ATL were identical, indicating that a human T-cell leukemia virus-type 1 (HTLV-1)-infected clone identical to the one that recently caused ATL was present in the original lymphoma tissue. Although we were unable to identify this clone as the cause of the previous ATL, the peripheral leukemia cells revealed an ATL clone that was present in the tumor cells of a lymph node diagnosed 26 years earlier. To our knowledge, this is the first report demonstrating survival of HTLV-1-infected clones for a quarter of a century in a patient with recurrent ATL.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"416-420"},"PeriodicalIF":1.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142885615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A practice-oriented genome-profiling study for acute myeloid leukemia using the novel HANDLE system: HM-screen-JAPAN02. 利用新型 HANDLE 系统对急性髓性白血病进行以实践为导向的基因组谱分析研究：HM-screen-JAPAN02.

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-01 Epub Date: 2024-12-16 DOI: 10.1007/s12185-024-03895-w

Hironori Arai, Naoko Hosono, SungGi Chi, Kentaro Fukushima, Daisuke Ikeda, Satoshi Iyama, Akihiko Gotoh, Takayuki Ikezoe, Chikashi Yoshida, Goichi Yoshimoto, Junya Kanda, Naoto Takahashi, Emiko Sakaida, Kensuke Usuki, Takahiro Yamauchi, Yosuke Minami

{"title":"A practice-oriented genome-profiling study for acute myeloid leukemia using the novel HANDLE system: HM-screen-JAPAN02.","authors":"Hironori Arai, Naoko Hosono, SungGi Chi, Kentaro Fukushima, Daisuke Ikeda, Satoshi Iyama, Akihiko Gotoh, Takayuki Ikezoe, Chikashi Yoshida, Goichi Yoshimoto, Junya Kanda, Naoto Takahashi, Emiko Sakaida, Kensuke Usuki, Takahiro Yamauchi, Yosuke Minami","doi":"10.1007/s12185-024-03895-w","DOIUrl":"10.1007/s12185-024-03895-w","url":null,"abstract":"HM-SCREEN-Japan is a multicenter collaborative project in Japan to evaluate the clinical utility of a cancer genome panel in the treatment of acute myeloid leukemia (AML). The HM-SCREEN-JAPAN02 study used the Amoy Myeloid Panel® with the HANDLE system, which enables efficient and rapid sequencing, as the genomic testing kit. The Amoy Myeloid Panel® targets 53 genes with established clinical significance or high prevalence. The study analyzed bone marrow fluid or peripheral blood. Multiple time points for submission were allowed to evaluate clonal changes over time. A total of 179 tests/145 patients with one or more pathogenic mutations (23 patients submitted specimens at multiple time points) were included in the analysis. A variety of patterns were detected, including acquisition of new resistance-associated genetic mutations and pathogenic mutations remaining after clinical remission. The median time required for sequencing and annotation was 8 days. TP53 and NRAS mutations were associated with increased risk of death (hazard ratio = 3.98 and 5.50, respectively). In a survey of physicians at the participating centers, 63% reported that the genomic panel was clinically useful, particularly for assessing clinical risk and evaluating indications for hematopoietic stem cell transplantation.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"378-387"},"PeriodicalIF":1.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

JSH practical guidelines for hematological malignancies, 2023: leukemia-6. Myelodysplastic syndromes (MDS). 2023年JSH血液恶性肿瘤实用指南：白血病-6。骨髓增生异常综合征（MDS）。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-01 Epub Date: 2025-01-14 DOI: 10.1007/s12185-024-03906-w

Yasushi Miyazaki

引用次数: 0

Ixazomib-induced angioedema. Ixazomib-induced血管性水肿。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-01 Epub Date: 2025-01-21 DOI: 10.1007/s12185-025-03919-z

Katsuro Ito, Naohiko Aozasa

引用次数: 0

Association between gene mutations and outcomes in Japanese high-risk AML patients: a phase 1/2 study of NS-87/CPX-351. 基因突变与日本高危AML患者预后之间的关系：NS-87/CPX-351的1/2期研究

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-02-27 DOI: 10.1007/s12185-025-03956-8

Hideki Makishima, Taisuke Mikasa, Kento Isogaya, Toshihiro Miyamoto, Takuji Yamauchi, Akira Yokota, Masahiro Onozawa, Kiyoshi Ando, Yoshiaki Ogawa, Kensuke Usuki, Takahiro Yamauchi, Shuichi Ota, Satoru Takada, Yasuyoshi Morita, Takayuki Ishikawa, Katsuto Takenaka, Junya Kuroda, Naohiro Sekiguchi, Toshiro Kawakita, Yasushi Miyazaki

{"title":"Association between gene mutations and outcomes in Japanese high-risk AML patients: a phase 1/2 study of NS-87/CPX-351.","authors":"Hideki Makishima, Taisuke Mikasa, Kento Isogaya, Toshihiro Miyamoto, Takuji Yamauchi, Akira Yokota, Masahiro Onozawa, Kiyoshi Ando, Yoshiaki Ogawa, Kensuke Usuki, Takahiro Yamauchi, Shuichi Ota, Satoru Takada, Yasuyoshi Morita, Takayuki Ishikawa, Katsuto Takenaka, Junya Kuroda, Naohiro Sekiguchi, Toshiro Kawakita, Yasushi Miyazaki","doi":"10.1007/s12185-025-03956-8","DOIUrl":"https://doi.org/10.1007/s12185-025-03956-8","url":null,"abstract":"This phase 1/2 study investigated the association between genetic characteristics and outcomes for NS-87/CPX-351 in Japanese patients with high-risk acute myeloid leukemia. Blood samples collected from 29 patients were analyzed using a 70-gene next-generation sequencing panel. The most frequently mutated genes were TP53 (44.8%), TET2 (24.1%), DNMT3A (13.8%), and NRAS (13.8%). The rates of composite complete remission (CRc; complete remission [CR] or CR with incomplete hematologic recovery [CRi]) were comparable between patients with and without mutations in TP53, TET2, DNMT3A, and NRAS (P = 0.571 for all). Notably, patients with TP53 mutations had a similar CRc rate (69.2% vs. 56.3%), but shorter overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS) compared to patients with wild-type TP53 (median OS: 7.43 vs. 18.18 months; P = 0.108, median EFS: 2.43 vs. 6.28 months; P = 0.012, median RFS: 1.48 vs. 10.19 months; P = 0.012). In conclusion, no gene mutations directly associated with the efficacy of NS-87/CPX-351 were found. While NS-87/CPX-351 achieved remission even in patients with TP53 mutations, relapse risk was higher in these patients. Therefore, it is advisable to consider treatment strategies such as early transplantation after achieving remission with NS-87/CPX-351, especially in patients with TP53 mutations.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Simple and early prediction of severe CAR-T-related adverse events after Axi-cel infusion by initial high fever. 通过初始高热简单和早期预测轴细胞输注后严重car - t相关不良事件。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-02-27 DOI: 10.1007/s12185-025-03957-7

Hiroya Wakabayashi, Seitaro Terakura, Kohei Ishigiwa, Fumiya Ohara, Shiho Hirano, Hirofumi Yokota, Shihomi Kuwano, Katsuya Furukawa, Kazuyuki Shimada, Takahiko Sato, Ryo Hanajiri, Hitoshi Kiyoi

{"title":"Simple and early prediction of severe CAR-T-related adverse events after Axi-cel infusion by initial high fever.","authors":"Hiroya Wakabayashi, Seitaro Terakura, Kohei Ishigiwa, Fumiya Ohara, Shiho Hirano, Hirofumi Yokota, Shihomi Kuwano, Katsuya Furukawa, Kazuyuki Shimada, Takahiko Sato, Ryo Hanajiri, Hitoshi Kiyoi","doi":"10.1007/s12185-025-03957-7","DOIUrl":"https://doi.org/10.1007/s12185-025-03957-7","url":null,"abstract":"Chimeric antigen receptor T-cell (CAR-T)-related adverse events (CAR-AEs), such as immune effector cell-associated neurotoxicity syndrome (ICANS) and cytokine release syndrome (CRS), can be life-threatening and may require high-dose steroids. Identifying patients at high risk for severe CAR-AEs in a simplified way is crucial for early therapeutic intervention. This retrospective study analyzed 44 patients treated with axicabtagene ciloleucel (Axi-cel) to identify predictive factors for severe CAR-AEs. We found that grade ≥ 3 ICANS, hemophagocytic syndrome, and ICU admission were associated with a greater need for high-dose steroids, which we defined as events associated with high-dose steroids (EHS). The incidence of EHS was significantly higher in patients who developed an initial fever (≥ 38.6 °C) within 24 h of CAR-T infusion (p < 0.001). Progression-free survival (PFS) was significantly shorter in patients with EHS compared to those without EHS (p < 0.001). Additionally, patients who developed a fever within 24 h and those with a peak fever of ≥ 38.6 °C both tended to have higher peak CAR-T counts compared to other patients. Our findings suggest that an initial fever (≥ 38.6 °C) within 24 h of Axi-cel infusion may predict severe CAR-AEs requiring high-dose steroids, and that EHS is associated with worse PFS.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk of ankylosing spondylitis in long-term follow-up of hematopoietic stem cell donors: impact of HLA-B27 status and donation type. 造血干细胞供者长期随访中强直性脊柱炎的风险：HLA-B27状态和供体类型的影响

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-02-27 DOI: 10.1007/s12185-025-03926-0

Sung-Chao Chu, Chia-Jung Hsieh, Shang-Hsien Yang, Kuo-Liang Yang, Kuei-Ying Su, Wei-Han Huang, Dian-Kun Li, Woei-Yau Kao, Szu-Chin Li, Sheng-Chuan Huang, Chi-Cheng Li, Ruey-Ho Kao, Tso-Fu Wang

{"title":"Risk of ankylosing spondylitis in long-term follow-up of hematopoietic stem cell donors: impact of HLA-B27 status and donation type.","authors":"Sung-Chao Chu, Chia-Jung Hsieh, Shang-Hsien Yang, Kuo-Liang Yang, Kuei-Ying Su, Wei-Han Huang, Dian-Kun Li, Woei-Yau Kao, Szu-Chin Li, Sheng-Chuan Huang, Chi-Cheng Li, Ruey-Ho Kao, Tso-Fu Wang","doi":"10.1007/s12185-025-03926-0","DOIUrl":"https://doi.org/10.1007/s12185-025-03926-0","url":null,"abstract":"Hematopoietic stem cell transplantation (HSCT) is a pivotal curative therapy for various hematologic diseases, and donor safety is paramount. A few cases of ankylosing spondylitis (AS) have been reported in healthy unrelated donors, but the incidence has not been previously described. This retrospective cohort study analyzed 1098 bone marrow (BM) and 3890 peripheral blood stem cell (PBSC) donors between January 1998 and December 2018, along with healthy participants from the donor registry using de-identified data from the Taiwan National Health Insurance Research Database. The overall AS incidences among donors and non-donors were both 0.38%. AS incidence did not differ between BM and PBSC donors and their matched counterparts. Individuals with HLA-B27 exhibited higher incidence rate ratios than those without HLA-B27 in both the BM and PBSC cohorts. In those individuals with HLA-B27, BM donors showed a relative risk of 3.85 (p = 0.0017) compared to non-donors, while the risk for PBSC donors was not significantly higher (1.36, p = 0.339). The findings suggest that while AS incidence among HSC donors is comparable to non-donors, HLA-B27 positivity is the main risk factor associated with AS development, particularly among BM donors. This study provides valuable insights into the safety of HSCT donation and long-term follow-up.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0